Clinical prospects for using the Ki67 proliferation index in lymphogenic metastases in breast carcinoma
- Authors: Balkanov A.S1, Gaganov L.E1, Rozanov I.D1, Shirikov E.I1
-
Affiliations:
- M.F. Vladimirsky Moscow Regional Clinical Research Institute
- Issue: Vol 23, No 3 (2020)
- Pages: 18-24
- Section: Articles
- URL: https://journals.eco-vector.com/1560-9596/article/view/112728
- DOI: https://doi.org/10.29296/25877313-2020-03-04
- ID: 112728
Cite item
Abstract
Full Text
About the authors
A. S Balkanov
M.F. Vladimirsky Moscow Regional Clinical Research Institute
Email: andreybalkanov@yandex.ru
Dr.Sc. (Med.), Head Department of Radiotherapy in the Section «Science»
L. E Gaganov
M.F. Vladimirsky Moscow Regional Clinical Research Institute
Email: 6844325@mail.ru
Dr.Sc. (Med.), Leading Research Scientist, Department of Morphological Diagnostics, Oncology Department
I. D Rozanov
M.F. Vladimirsky Moscow Regional Clinical Research InstituteResearch Scientist, Department of Radiotherapy
E. I Shirikov
M.F. Vladimirsky Moscow Regional Clinical Research InstituteResearch Scientist, Department of Radiotherapy
References
- Гуров А.Н., Балканов А.С., Катунцева Н.А., Огнева Е.Ю. Анализ онкозаболеваемости и смертности населения Московской области за 2014 год. Альманах клинической медицины. 2015; 41:6-12
- Jin X., Mu P. Targeting breast cancer metastasis. Breast Cancer (Auckl). 2015; 9(Suppl 1):23-34. doi: 10.4137/BCBCR.S25460.
- Richardson L.C., Henley S.J., Miller J.W., Massetti G., Thomas C.C. Patterns and trends in age-specific black-white differences in breast cancer incidence and mortality - United States. 1999-2014. Morbidity and Mortality Weekly Report. 2016; 65(40):1093-1098.
- Lee E.S., Jung S.Y., Kim J.Y., Kim J.J., Yoo T.K., Kim Y.G., Lee K.S., Lee E.S., Kim E.K., Min J.W., Han W, Noh D.Y., Moon H.G. Identifying the potential long-term survivors among breast cancer patients with distant metastasis. Ann. Oncol. 2016; 27(5):828-833.
- Liu X., Guan Y., Zhang W., Liu S., Liu J., Wang L., Niu Y. Predictors of recurrence in breast cancer subtypes with negative lymph node in a Chinese population. Int. J. Clin. Exp. Pathol. 2014; 7(6):3202-3212.
- Nordenskjold A.E., Fohlin H., Albertsson P., Arnesson L.G., Chamalidou C., Einbeigi Z., Holmberg E., Nordenskjold B., Karlsson P. No clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes. Ann. Oncol. 2015; 26(6):1149-1154.
- Tran H.D., Luitel K., Kim M., Zhang K., Longmore G.D., Tran D.D. Transient SNAIL1 expression is necessary for metastatic competence in breast cancer. Cancer Res. 2014; 74(21):6330-6340. doi: 10.1158/0008-5472.CAN-14-0923.
- Jiang Y., Xu H., Zhang H., Ou X., Xu Z., Ai L., Sun L., Liu C. Nomogram for prediction of level 2 axillary lymph node metastasis in proven level 1 node-positive breast cancer patients. Oncotarget. 2017; 8(42):2389-72399. doi: 10.18632/oncotarget.20395.
- Dowsett M., Nielsen T.O., Hern R.A., Bartlett J., Coombes R.C., Cuzick J., Ellis M., Henry N.L., Hugh J.C., Lively T., McShane L., Paik S., Penault-Llorca F., Prudkin L., Regan M., Salter J., Sotiriou C., Smith I.E., Viale G., Zujewski J.A., Hayes D.F. Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group. J. Natl. Cancer Inst. 2011; 103(22): 1656-1664. doi: 10.1093/jnci/djr393.
- Kilickap S., Kaya Y., Yucel B., Tuncer E., Babacan N.A., Elagoz S. Higher Ki67 expression is associates with unfavorable prognostic factors and shorter survival in breast cancer. Asian Pac. J. Cancer Prev. 2014; 15(3):1381 -1385.
- Petrelli F., Viale G., Cabiddu M., Barni S. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res. Treat. 2015; 153(3):477-491.
- Karlsson P., Cole B.F., Chua B.H., Price K.N., Lindtner J., Collins J.P., Kovacs A., Thurlimann B., Crivellari D., Castiglione-Gertsch M., Forbes J.F., Gelber R.D., Goldhirsch A., Gruber G. Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report. Ann. Oncol. 2012; 23:2852-2858.
- Viani G.A., Godoi da Silva L.B., Viana B.S. Рatients with N1 breast cancer: Who could benefit from supraclavicular fossa radiotherapy? Breast. 2014; 23(6):749-753.
- Mittendorf E.A., Ballman K.V., McCall L.M., Yi M., Sahin A.A., Bedrosian I., Hansen N., Gabram S., Hurd T., Giuliano A.E., Hunt K.K. Evaluation of the stage IB designation of the American Joint Committee on Cancer staging system in breast cancer. J. Clin. Oncol. 2015; 33(10): 1119-1127.
- Zhao S., Xu L., Liu W., Lv C., Zhang K., Gao H., Wang J., Ma R. Comparison of the expression of prognostic biomarkers between primary tumor and axillary lymph node metastases in breast cancer. Int. J. Clin. Exp. Pathol. 2015; 8(5):5744-5748.
- Park D., Karesen R., Noren T., Sauer T. Ki-67 expression in primary breast carcinomas and their axillary lymph node metastases: clinical implications. Virchows Arch. 2007; 451(1): 11 -18. doi: 10.1007/s00428-007-0435-2.
- Furet E., Bouchtaoui M.E., Feugeas J., Miquel C., Leboeuf C., Beytout C., Bertheau P., Rhun E., Bonneterre J., Janin A., Bousquet G. Increased risk of brain metastases in women with breast cancer and p16 expression in metastatic lymph-nodes. Oncotarget. 2017; 8(23):37332-37341. doi: 10.18632/oncotarget.16953
- Tawfik K., Kimler B.F., Davis M.K., Fan F., Tawfik O. Ki-67 expression in axillary lymph node metastases in breast cancer is prognostically significant. Hum. Pathol. 2013; 44(1):39-46. doi: 10.1016/j.humpath.2012.05.007.